Oriflame has stepped up its sales by 1% at CER in Q4 and 3% at CER in FY18. Unit sales are still dropping (-3% in Q4) and the poor growth is still driven by price/mix. The company is facing challenging conditions in Asia and Turkey. Sales in Q1 19 to date are down 7% at CER.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weak 2018 as expected but a likely very tough 2019
- Published:
14 Feb 2019 -
Author:
Rim BEN SALAH -
Pages:
3
Oriflame has stepped up its sales by 1% at CER in Q4 and 3% at CER in FY18. Unit sales are still dropping (-3% in Q4) and the poor growth is still driven by price/mix. The company is facing challenging conditions in Asia and Turkey. Sales in Q1 19 to date are down 7% at CER.